[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Cantargia's TRIFOUR trial results are out, with Redeye commenting on the negative topline data. FrillePelle and Redeye are providing commentary on the data and the company's future.
Cantargia ($canta) is a biotechnology company.
Engagements 24-Hour Chart Data
Current Value: XXXXX
Daily Average: XXX
1 Week: XXXXX +1,528%
1 Month: XXXXXX +473%
1-Year High: XXXXX on 2025-07-17
1-Year Low: X on 2025-05-09
Social Network | X |
---|---|
Engagements | XXXXX |
Mentions 24-Hour Chart Data
Current Value: XX
Daily Average: X
1 Week: XXX +1,357%
1 Month: XXX +1,225%
1-Year High: XX on 2025-07-23
1-Year Low: X on 2025-04-27
Social Network | X |
---|---|
Mentions | XX |
Creators 24-Hour Chart Data
XX unique social accounts have posts mentioning $canta in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
1 Week: XX +140%
1 Month: XX +333%
1-Year High: XX on 2025-07-18
1-Year Low: X on 2025-04-27
The most influential creators that mention $canta in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@FrillePelle | X | XXX | X | XXX |
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% -XX%
1-Year High: XXX% on 2025-07-03
1-Year Low: XX% on 2025-07-20
Most Supportive Themes
Most Critical Themes
Network engagement breakdown:
Network | Positive | % | Neutral | % | Negative | % |
---|---|---|---|---|---|---|
X | XXX | XX% | XXX | XX% | XX | X% |
Total | XXX | XX% | XXX | XX% | XX | X% |
Top assets mentioned In the posts about $canta in the last XX hours
AbbVie Inc (ABBV) Scholar Rock Holding Corporation Common Stock (SRRK) Immunogen Inc (IMGN) Pfizer, Inc. (PFE) Ellipsis (EPS) Lantheus Holdings, Inc (LNTH)
Top topics mentioned In the posts about $canta in the last XX hours
stocks healthcare, $4768t, $4578t, investment, discussions, $abbv, abus, $lenz, $ghrs, $fna, $phat, $rgnx, $siga, $urgn, $crbp, $aplt, $cdmo, $oric, $repl, $lxrx, $abvx, $adpt, $tvtx, $cuv, $abus, $eras, $meso, $avbp, $stok, $crgx, $zyme, $pahc, $ontx, $svra, $wve, $cvac, $nuvb, $auph, $ctkb, $icpt, $plrx, $srrk, generated, rates, dag, $imgn, $pfe, $580m, $33m, acquisition, eps, $eps, coins defi, beta, att, ssc, breakthrough, alot, har, virtual, cart, kan, gns, $xbit, $lnth, stocks defense, abstract, frn, correlation, checkpoint, holders
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Further comprehensive details of the TRIFOUR study including additional secondary end points and subgroup analyses are expected to be presented at a forthcoming scientific conference. $CANTA #CANTARGIA #IL1RAP"
@FrillePelle on X 2025-07-23 14:30:09 UTC XXX followers, XXX engagements
"This historical context suggests that the observed response rates in the TRIFOUR trial even without a significant difference between the nadunolimab and control arms in phase X remain clinically relevant $CANTA #CANTARGIA #IL1RAP"
@FrillePelle on X 2025-07-23 14:06:41 UTC XXX followers, XXX engagements
"@Redeye_ Tough break for Cantargia with the TRIFOUR data. Markets might not take it wellkinda lines up with what @CarterVanceUSAs been saying about biotech risks lately. Rough day for $CANTA holders"
@ngiban1980 on X 2025-07-18 14:50:02 UTC X followers, XX engagements
"Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case for Cantargia. $CANTA"
@Redeye_ on X 2025-07-18 07:00:17 UTC 14.5K followers, 1647 engagements